Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Calls for Lifting of Shipment Restrictions for 130 Generic API/Specifications after Survey Finds YOY Rise in Supplies
December 14, 2021
- Doctor, Pharmacist Reps Call for Expanding Fees for Biosimilars: Chuikyo
December 13, 2021
- LDP Project Team to Compile Proposal to Move Up Booster Interval
December 13, 2021
- METI to Dole Out Support for “Dual-Use” Production Bases to Boost Pandemic Preparedness
December 13, 2021
- Sakigake Status Withdrawn for Takeda’s Pevonedistat: MHLW
December 10, 2021
- Fiscal Discipline for Drug Spending Could Be Discussed towards FY2023: MOF Budget Examiner
December 10, 2021
- E Keppra Generics from 12 Firms to Join NHI Price List, Patanol and Velcade AGs Too
December 9, 2021
- Payers Want Low-Generic Fee Cuts Applied to Medical Institutions Too: Chuikyo
December 9, 2021
- No Chuikyo Members Call for Formulary Incentives under Medical Fee Schedule
December 9, 2021
- Moderna COVID-19 Booster Up for Panel Review on Dec. 15
December 9, 2021
- MHLW Warns against Hoarding on 17 APIs as Hitachi Fire Stirs Supply Worries
December 8, 2021
- Shorter Booster Interval for All Citizens Difficult: Health Minister
December 8, 2021
- Written Pledge Rule on Generic Listing to Continue after 2021; Companies Feel Pressure for Stable Supplies
December 7, 2021
- BMS’ Second CAR-T Therapy Ide-Cel in Line for Approval in January
December 7, 2021
- MHLW to Prepare List of Priority Infectious Diseases by March-End, Set Up Study Group in December
December 7, 2021
- Japan Panels Agree to Add Myocarditis as ADRs for Pfizer, Moderna Vaccines
December 6, 2021
- 2 mRNA Jabs Ordered to Add Myocarditis to ADR List: Label Revision
December 6, 2021
- Panel OKs Outline of Emergency Approval System Based on “Presumed” Efficacy
December 6, 2021
- MHLW Issues Revised Drug Distribution Guidelines; Effective January 1
December 6, 2021
- MOF Panel’s Budget Proposal Pushes Macroeconomic Indexing, No Adjustment Rate
December 6, 2021
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…